Treating iron deficiency in children

Pediatric and Adolescent Iron Deficiency should be treated with age‑appropriate iron repletion—typically oral elemental iron at 3–6 mg/kg/day (maximum about 60 mg elemental iron/day) until hemoglobin (Hb) and ferritin normalize, with therapy continued for at least three months after hemoglobin correction. Baseline assessment includes a complete blood count (CBC) and serum ferritin; WHO hemoglobin cutoffs commonly used are <11.0 g/dL for children 6–59 months and <11.5 g/dL for children 5–11 years. Expect a hemoglobin rise of approximately 1 g/dL within 2–4 weeks of effective therapy.

Mechanistically, iron replacement restores erythropoiesis by supplying elemental iron for hemoglobin synthesis; laboratory tools such as CBC, serum ferritin, and transferrin saturation quantify response and iron stores. Clinical frameworks from the American Academy of Pediatrics (AAP) and WHO guide screening and interpretive thresholds for iron deficiency in children, while reticulocyte count is a rapid marker of marrow response. For adolescents, adolescent iron deficiency screening should target menstruating females and other at‑risk groups; monitoring ferritin levels in children helps distinguish depleted stores from acute‑phase elevation and guides whether oral vs IV iron pediatrics is indicated.

A critical nuance is the frequent misuse of adult thresholds and conflation of low ferritin with overt anemia: ferritin <12 µg/L generally indicates iron depletion in young children even when hemoglobin remains normal, whereas iron deficiency anemia pediatric treatment is reserved for cases with low Hb plus low ferritin or transferrin saturation. In a common outpatient scenario, a toddler with ferritin 8 µg/L and Hb 11.2 g/dL benefits from targeted oral supplementation and dietary counseling rather than immediate IV therapy. Intravenous iron should be reserved for clear indications such as documented malabsorption, persistent intolerance to oral formulations, ongoing bleeding, chronic kidney disease, or failure of optimized oral therapy after 4–8 weeks when adherence and dosing have been confirmed.

Practical application includes age‑specific screening at 12 months and targeted adolescent screening, initiation of oral elemental iron at 3–6 mg/kg/day with counseling on administration with vitamin C and avoidance of calcium around doses, and laboratory recheck at about four weeks to document reticulocytosis and hemoglobin rise. If ferritin remains low after hemoglobin correction or if oral therapy is not tolerated, escalation to IV iron is appropriate per specialty protocols. This page contains a structured, step‑by‑step clinical framework for screening, treatment selection, monitoring, and prevention.